Aurevia announces a strategic restructuring that will result in the formation of two independent companies: Aurevia and Labquality. This move is designed to unlock greater value for customers, partners, and stakeholders by allowing each entity to focus more sharply on its core business and market opportunities.
Under the new structure, Aurevia will continue as a Contract Research Organization (CRO) and Quality Assurance and Regulatory Affairs (QARA) services provider, while Labquality will focus on External Quality Assessment (EQA) services. Aurevia will serve medical devices and in vitro diagnostic manufacturers and pharmaceutical companies, and Labquality offers services to clinical laboratories and healthcare units. The split is expected to be finalized by the year-end, with both companies operating independently from January 1st, 2026.
After the split, each company will be better positioned to invest in and accelerate business growth to its specific customer base. With streamlined operations, both Aurevia and Labquality can respond more quickly to market changes and customer needs. Moreover, customers will benefit from dedicated teams and solutions that align closely with their industry challenges.
"This is a pivotal moment in our journey. By creating two focused companies, we are empowering each to pursue its strategic vision with greater agility and precision. Our customers will benefit from better-focused businesses and clearer service offers. This split also allows us to sharpen the brand identities of Aurevia and Labquality to better serve our distinct customer segments,” says CEO Juha-Pekka Nuutinen from Aurevia.
A dedicated transition team is overseeing the split to ensure a smooth and transparent process for all stakeholders and seamless continuation of the business and customer relationships.
For queries, please contact:
For queries, please contact
Juha-Pekka Nuutinen
Share this article
